Frontiers in Cell and Developmental Biology · Oct 31, 2026
Recent advances in incretin signaling and naturally derived modulators for osteoporosis and osteoarthritis: from metabolic regulation to skeletal protection
By Xiaxia Wang, Yonglin Liang, Jingyu Li et al.
The incretin system, primarily composed of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), is traditionally recognized for coupling nutrient intake with pancreatic hormone secretion and metabolic regulation. However, accumulating evidence indicates that incretin signaling also contributes to musculoskeletal homeostasis by influencing osteoblast and osteoclast activity, bone marrow microenvironment, synovial inflammation, chondrocyte function, pain responses, and extracellular matrix metabolism. These findings have highlighted the potential involvement of incretin pathways in osteoporosis (OP) and osteoarthritis (OA), although the underlying mechanisms remain incompletely understood. The clinical application of GLP-1 receptor agonists (GLP-1RAs) and emerging dual- and multi-receptor agonists has further stimulated interest in their skeletal and joint effects. While these therapies provide substantial metabolic benefits, concerns regarding gastrointestinal intolerance, reduced nutrient intake, weight loss-associated loss of lean mass, and potential musculoskeletal consequences warrant further evaluation, particularly in populations at risk of osteoporosis, sarcopenia, and functional decline. This has prompted increasing attention toward strategies that enhance endogenous incretin activity rather than relying solely on sustained receptor activation. Natural-derived modulators, including traditional Chinese medicine formulas, plant-derived compounds, dietary components, and polyphenols, represent potential regulators of endogenous incretin responses. Experimental studies indicate that they may influence incretin activity through regulation of the gut microbiota and its metabolites, bile acid signaling, intestinal nutrient-sensing pathways, endogenous GLP-1 release, dipeptidyl peptidase-4 (DPP-4) activity, and downstream signaling associated with incretin receptors. This review examines the current evidence linking GLP-1/GLP-1R and GIP/GIPR signaling with OP and OA, and discusses the benefits and limitations of pharmacological incretin-based therapies from a musculoskeletal perspective. Particular attention is given to natural-derived modulators and to the extent to which their reported metabolic, skeletal, and joint effects can be attributed to incretin-related mechanisms. Finally, we identify major gaps in causal evidence, safety evaluation, and clinical translation that should be addressed before incretin-modulating strategies can be more broadly considered in the prevention or management of OP and OA.